BioAge Labs, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
BIOA$5.78+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Unaudited Conde nsed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(54,662) | $(49,980) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 8,969 | 4,258 |
| Depreciation expense | 144 | 120 |
| Loss on extinguishment of debt | — | 250 |
| Non-cash interest expense | 156 | 987 |
| Non-cash lease expense | 115 | 3 |
| (Gain) loss from changes in fair value on warrants | (6) | 384 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (515) | — |
| Prepaid expenses and other current assets | (1,481) | (1,644) |
| Other assets | 13 | — |
| Accounts payable | 3,095 | 132 |
| Accrued expenses and other current liabilities | (4,766) | 2,419 |
| Deferred revenue | (4,438) | — |
| Deferred grant income | — | (3,313) |
| Net cash used in operating activities | (53,376) | (46,384) |
| INVESTING ACTIVITIES | ||
| Purchase of property and equipment | (607) | (340) |
| Purchases of marketable securities | (114,431) | — |
| Maturities of marketable securities | 34,250 | — |
| Net cash used in investing activities | (80,788) | (340) |
| FINANCING ACTIVITIES | ||
| Proceeds from Series D issuance | — | 170,000 |
| Issuance costs paid on Series D issuance | — | (542) |
| Proceeds from initial public offering, net of underwriting discounts and commissions | — | 184,140 |
| Issuance costs paid on initial public offering and private placement | — | (3,268) |
| Proceeds from issuance of common shares through private placement, net of placement agent fees | — | 9,858 |
| Term loan principal payments | (4,500) | (4,500) |
| Deferred offering costs paid | (44) | — |
| Proceeds from issuance of common shares upon stock option exercises | — | 609 |
| Net cash (used in) provided by financing activities | (4,544) | 356,297 |
| Effect of changes in exchange rate on cash and cash equivalents | (68) | (56) |
| Net (decrease) increase in cash and cash equivalents | (138,776) | 309,517 |
| Cash, cash equivalents and restricted cash at beginning of period | 354,349 | 24,957 |
| Cash and cash equivalents at end of period | $215,573 | $334,474 |
| Supplemental non-cash disclosure: | ||
| Unpaid equity issuance costs included in accounts payable and accrued expenses | $— | $1,249 |
| Conversion of convertible promissory notes into Series D-1 redeemable convertible preferred stock | $— | $40,651 |
| Conversion of redeemable convertible preferred stock into common stock upon initial public offering | $— | $342,831 |
| Purchases of property and equipment in accounts payable and accrued expenses | $42 | $— |
| Cash paid for interest | $526 | $1,145 |
| Deferred offering costs included in accounts payable, accrued expenses, and other current liabilities | $255 | $— |
| Right-of-use assets obtained in exchange for lease obligation | $3,106 | $282 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.